Quantum BioPharma Ltd (fra:0K91) Share Price

Company Profile

Business description
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Contact
1 Adelaide Street East
Suite 801
TorontoONM5C 2V9
CAN
T: +1 833 304-0323
https://www.quantumbiopharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7

Recommended

Fear outweighs fundamentals as ASX share reaffirms outlook.

Nathan Zaia | 29 October 2026

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,033.20	20.60	0.23%
CAC 40	7,970.00	83.04	1.05%
DAX 40	26,039.68	335.66	1.31%
Dow JONES (US)	52,342.56	132.54	-0.25%
FTSE 100	10,722.07	27.57	0.26%
HKSE	23,335.66	377.01	1.64%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	63,213.36	1,446.11	-2.24%
NZX 50 Index	13,797.00	86.83	0.63%
S&P 500	7,720.39	23.59	-0.30%
S&P/ASX 200	8,916.40	24.60	0.28%
SSE Composite Index	3,640.54	10.90	-0.30%